Eli Lilly offers lackluster outlook for 2016

Shares rise as optimism remains high for the medicines that are in development.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.